Eli Lilly is trading at $1,206.78, up 3.45%, alongside a healthcare sector gain of 1.64% in the regular session; no direct link has been established.
- UnitedHealth’s better-than-expected third-quarter results and raised profit outlook provided positive healthcare-sector news, but no source directly ties them to Lilly’s move.
- No clear company-specific catalyst was identified; RBC’s reported “outperform” rating reissue is dated October 14 and does not establish a direct reason for the intraday rise.